TE vs Androgenetic Alopecia

What is Androgenetic Alopecia (AGA)?

Telogen effluvium (TE) and androgenetic alopecia (AGA) are among the most common non-scarring hair-loss diagnoses, but they behave very differently over time. TE is primarily a hair-cycle "traffic jam": a larger-than-usual number of follicles shift into telogen (resting) and then shed a few months later, often after a trigger such as illness, fever, surgery, childbirth, major stress, medication changes, or nutritional deficiency. TE typically starts abruptly, produces noticeably increased shedding, and often improves once the trigger resolves, with regrowth following on its own timeline.

AGA is patterned, progressive follicle miniaturization driven by genetic susceptibility and androgen signaling, particularly dihydrotestosterone (DHT) in androgen-sensitive scalp regions. It tends to cause gradual thinning — often with a part that widens over time in many women and bitemporal or vertex thinning in many men — and it usually requires ongoing treatment to stabilize and improve.

Both conditions can overlap: an episode of TE can "unmask" early AGA because shedding suddenly reveals underlying miniaturization, and chronic TE can coexist with female-pattern hair loss. Because coexistence changes prognosis and treatment strategy, the most practical approach is to evaluate three things in parallel: shedding intensity, patterned miniaturization, and whether a trigger occurred 2–4 months earlier.

Quick Comparison of High-Yield Clinical Features

Hair Biology and Pathophysiology

Human scalp follicles cycle through anagen (growth), catagen (transition), and telogen (rest), with most scalp hairs normally in anagen. A commonly cited telogen duration is on the order of a few months, which matters because it explains the classic TE delay: the trigger happens first, the follicle shifts phases, and shedding appears later.

Telogen Effluvium

TE is best understood as a reaction pattern of the hair cycle rather than a single disease mechanism. Many triggers — systemic stressors, medications, nutritional deficits — can push more follicles than usual to exit anagen and enter telogen in a relatively synchronized way, leading to increased shedding weeks-to-months later.

In post-infectious TE, proposed contributors include inflammatory cytokine signaling, physiologic stress, and secondary effects like nutritional depletion or medication exposures, although causality is often difficult to prove in retrospective datasets.

Chronic TE is controversial as a distinct entity. A 2023 systematic review found substantial heterogeneity in definitions and incomplete exclusion of secondary causes across published "chronic TE" cases, concluding that many cases labeled chronic TE may actually represent early female-pattern hair loss or persistent/recurring secondary triggers. It also highlighted that biopsy findings in purported chronic TE typically show a normal terminal-to-vellus ratio, which helps separate it from AGA when sampling is adequate.

Androgenetic Alopecia

AGA is characterized by progressive miniaturization of terminal follicles into thinner, shorter hairs (often described as "vellus-like" or intermediate hairs) in androgen-sensitive scalp regions. DHT binding to androgen receptors in susceptible follicles is a core pathway, with downstream signaling changes that shorten anagen and contribute to miniaturization over repeated cycles.

Genetics are strongly implicated and AGA is typically polygenic with variable expressivity. Environmental and systemic associations (for example, metabolic markers in some populations) have been reported, but these are associations rather than proof of causation for hair loss.

Epidemiology and Risk Factors

Telogen Effluvium

The true incidence and prevalence of TE are often described as unclear because many cases are subclinical or never formally diagnosed. Women are frequently overrepresented in clinical cohorts, in part because shedding is more noticeable with longer hair and because help-seeking patterns differ by gender.

Risk factors and triggers are broad and context-dependent. Commonly cited triggers include febrile illness or systemic infection, surgery, childbirth/postpartum hormonal shifts, significant dietary restriction or rapid weight loss, iron deficiency, thyroid disease, and medication initiation/cessation/dose changes.

After COVID-19, multiple studies and dermatology public-health guidance describe TE as a recognized pattern of temporary shedding that often begins a few months after infection or recovery. One patient-facing synthesis notes that about 20% of people in studies developed temporary shedding after COVID-19, though estimates vary by study design and population.

Androgenetic Alopecia

AGA is widely described as the most common type of hair loss. Reported prevalence varies by sex, age, and population; one recent review states that AGA affects about 80% of men and nearly 50% of women by around age 70 in some cohorts, while an expert consensus paper cites global estimates around 40% of men and 30% of women (these figures reflect differences in methodology and definitions).

Risk factors for AGA include age, family history/genetic predisposition, and androgen sensitivity. In women, evaluation for hyperandrogenism is particularly relevant when there are accompanying signs such as hirsutism, acne, or menstrual irregularities, because it can influence treatment choices.

Clinical Presentation and Expected Timelines

What Patients Usually Notice

TE typically presents as increased daily shedding, often described as "handfuls" of hair when washing, brushing, or on the pillow, with relatively preserved hairline and without a classic patterned recession. Many people can recall a trigger 2–4 months earlier, though a trigger may be absent or not recognized. Trichodynia (scalp discomfort/pain) and pruritus can occur, including in post-infectious TE cohorts.

AGA usually presents as progressive thinning rather than dramatic episodic shedding, although shedding can coexist. In women, key clinical features include central scalp thinning with part widening (sometimes with frontal accentuation) and preservation of follicular openings. In men, typical patterns include frontotemporal recession and/or vertex thinning.

Typical Timelines

TE after illness/stress: A "classic" pattern is onset of shedding roughly 2–4 months after the inciting event, with shedding often lasting a few months and regrowth following. Dermatology guidance summarizing post-COVID shedding commonly describes shedding beginning about 2–3 months after infection, lasting about 3–6 months, and then improving with regrowth over subsequent months. These timelines are typical patterns, not guarantees.

AGA: AGA progresses over years. Treatment response is usually assessed over months: topical minoxidil commonly requires several months before visible improvement, and androgen-pathway therapies similarly require time and continued use. Use our hair growth calculator to get a sense of your expected regrowth timeline.

Diagnostic Approach and Differential Diagnosis

A high-quality diagnosis usually comes from integrating history, examination, and (when needed) trichoscopy and focused testing. In ambiguous cases, scalp biopsy remains the most definitive way to distinguish diffuse TE from early diffuse AGA because it can quantify miniaturization and follicle ratios.

History

Key TE questions include: a triggering event 2–4 months earlier (illness with fever, surgery, childbirth, major dietary change/weight loss, new medications or dose changes), the abruptness of onset, and whether shedding is globally increased. TE cohorts after COVID-19 frequently fit this structure and can include scalp symptoms like trichodynia or pruritus.

Key AGA questions include: long-term gradual thinning, family history, age of onset, and in women, symptoms of hyperandrogenism or menstrual irregularities that may suggest endocrine contributors and guide therapy selection.

Physical Examination

TE often shows diffuse reduction in density without loss of follicular openings and without a patterned recession. A hair-pull test can be positive during active shedding, though it may turn negative as the episode wanes. In a post-COVID TE series, about half had a positive hair-pull test at presentation, consistent with timing effects.

AGA typically shows a patterned distribution and increased part width over time in many women; in men, characteristic frontotemporal and/or vertex thinness is common. Preservation of follicular ostia supports a non-scarring process, and progression pattern helps separate AGA from purely shedding-driven processes.

Trichoscopy

Trichoscopy is especially helpful because it converts "is it shedding or thinning?" into observable follicle patterns. In AGA, widely cited features include shaft diameter heterogeneity, increased thin/vellus hairs, perifollicular discoloration (peripilar sign), and variable yellow dots.

In TE, dermoscopy generally shows relatively uniform shaft diameter (limited variability), with increased empty follicular ostia and evidence of regrowth in many cases. In a post-COVID TE cohort, trichoscopy commonly showed short regrowing hairs and empty follicles, supporting the regrowth-and-shedding pattern typical of TE.

Quantifying Shedding and Caliber

Wash-based shedding tests can be useful when the story is unclear or when TE and AGA may be coexisting. A refined wash test study demonstrated much higher shedding counts in TE than in AGA and normal controls, and also found that AGA cases had smaller mean shedding-hair diameter and a higher proportion of vellus hairs than TE and controls.

A practical implication: "high shedding count with mostly terminal hairs" supports TE, while "increased small-caliber/vellus hairs" supports AGA or AGA plus TE. This logic is consistent with both classic modified wash test frameworks and newer wash-test refinements.

Laboratory Tests

Laboratory testing is often used to look for treatable contributors, but evidence supporting broad "panel testing" for every TE case is limited. A 2021 review of commonly ordered TE labs (ferritin/iron indices, anemia evaluation, vitamin D, thyroid tests, zinc) emphasized limited controlled evidence for many associations and limited proof that supplementation alone leads to regrowth in TE, particularly in the absence of clinically meaningful deficiency.

That said, targeted testing is still clinically common when history suggests risk. In diffuse shedding, many clinicians prioritize evaluation for iron deficiency and thyroid dysfunction as common and potentially treatable contributors, while interpreting ferritin cautiously because it is an acute-phase reactant and because thresholds for "hair-relevant ferritin" are debated across sources.

In suspected AGA, baseline labs are often not necessary if clinical findings are clear, but in women with signs of hyperandrogenism, evaluation of androgen levels and related endocrine testing can be indicated to guide therapy and exclude rare androgen-excess disorders.

Scalp Biopsy: Indications and Expected Histology

A biopsy is most helpful when:

• Shedding is chronic or atypical, and TE vs diffuse AGA is unclear.
• Scarring alopecia is in the differential (loss of follicular openings, perifollicular erythema with scarring patterns).
• There is poor response to appropriate first-line management and the diagnosis needs confirmation.

Expected biopsy differences:

• TE: generally preserved follicle number and preserved terminal-to-vellus ratio (especially in chronic TE), with increased telogen follicles or altered anagen-to-telogen ratios but without the degree of miniaturization expected in AGA.
• AGA: decreased terminal-to-vellus ratio and evidence of miniaturization; a 2025 clinical review in women notes decreased anagen-to-telogen and terminal-to-vellus ratios as typical findings, and discusses perifollicular inflammation in a substantial portion of biopsies, supporting the "microinflammation" concept in some cases.

Sampling caveat: Biopsy interpretation depends heavily on technique, site selection, and whether horizontal sections are used. Some literature emphasizes that multiple samples can improve diagnostic accuracy in challenging diffuse alopecia.

Differential Diagnosis

The most important differentials depend on whether the process is non-scarring vs scarring and whether shedding vs breakage vs focal loss is present.

For diffuse non-scarring shedding/thinning, major considerations include TE, diffuse AGA (especially early female-pattern hair loss), diffuse alopecia areata (including "incognita"), medication-related effluvium, thyroid disease, iron deficiency/anemia, and systemic illness.

For scarring alopecia considerations (often suggested by loss of follicular openings and/or perifollicular erythema with progression), entities such as frontal fibrosing alopecia or central centrifugal cicatricial alopecia may be relevant, and biopsy is often recommended. Consider consulting one of our recommended hair loss specialists for a thorough work-up.

Management and Treatment

Evidence strength differs sharply between TE and AGA. AGA has multiple randomized trials and meta-analyses for core pharmacologic options. TE management is usually trigger-focused and time-based, with fewer high-quality intervention trials, although newer studies are emerging for certain nutraceutical approaches. For a broader overview, see our top 10 treatments for telogen effluvium.

Telogen Effluvium

Acute TE

The cornerstone is identifying and removing the trigger when possible. In acute TE, reassurance and expectation-setting are not "soft" interventions; they directly reduce unnecessary testing, harmful over-treatment, and the cycle of stress that can worsen patient distress.

Common components:

• Trigger management: review medications and recent changes; address acute illness recovery; manage scalp inflammatory disorders if present (for example, seborrheic dermatitis); stabilize nutrition and weight; evaluate for postpartum context and counsel on expected course.
• Targeted deficiency correction: correct documented deficiencies (iron deficiency anemia, confirmed thyroid disorder, confirmed vitamin deficiencies) rather than using supplements indiscriminately. The evidence base is mixed, and at least one review emphasizes the lack of controlled evidence that supplementation alone reliably produces regrowth in TE, even though correcting true deficiencies is still medically appropriate.
• Optional pharmacologic support: topical minoxidil is sometimes used to support regrowth or address overlap with AGA, but TE-specific efficacy metrics are largely unspecified in high-quality trials, and recommendations are often extrapolated from AGA evidence.

Expected timeline: shedding often starts a few months after a trigger and then gradually improves; patient-facing dermatology guidance for post-COVID shedding describes shedding lasting about 3–6 months with regrowth beginning as shedding resolves and complete regrowth commonly within months.

Chronic TE

For chronic shedding beyond six months, the management goal shifts from "wait for it to pass" to "verify the diagnosis and rule out ongoing drivers." A 2023 systematic review argues that many "chronic TE" diagnoses reflect incomplete exclusion of secondary causes or early female-pattern hair loss, underscoring why reassessment is not optional.

Practical chronic TE structure:

• Re-check for persistent triggers (dietary restriction, chronic disease activity, inflammatory scalp disease, medication-related effluvium).
• Reconsider overlap with AGA using trichoscopy or wash-test metrics, because TE and AGA frequently coexist and chronic TE labels can mask early AGA.
• Consider biopsy when miniaturization is uncertain and diagnosis will change management.

TE Treatment Options and Evidence

Androgenetic Alopecia

AGA management is typically long-term and combination-based, grounded in therapies that either improve follicle function (minoxidil) or reduce androgen signaling in follicles (5α-reductase inhibitors in many men; antiandrogens in selected women).

Topical Minoxidil (Men and Women)

Evidence syntheses and reviews consistently find topical minoxidil improves hair density compared with placebo within 16–48 weeks in both men and women. One evidence summary describes improvements on the order of about 21 hairs/cm² vs 5–9 hairs/cm² with placebo across trials, though clinical significance varies and many studies focus on hair counts rather than patient-centered outcomes.

In women, a therapeutic update reports meta-analytic improvement for 2% topical minoxidil vs placebo after 24 weeks and notes that adherence is essential, with first visible results often after 4–6 months and indefinite continuation needed to maintain gains. It also emphasizes counseling around early "shedding" after initiation, which commonly leads to premature discontinuation if not anticipated.

Side effects include scalp irritation/contact dermatitis (often related to vehicle components), unwanted facial hypertrichosis, and an initial telogen shedding phase early in use.

Oral Minoxidil (Low-Dose, Off-Label for AGA)

Oral minoxidil is increasingly used off-label when topical adherence is poor or response is inadequate. In a randomized trial in men, 5 mg oral minoxidil daily for 24 weeks was not superior to 5% topical minoxidil twice daily, with different adverse-effect profiles (for example, higher hypertrichosis and headache rates with oral therapy).

Safety data from a large multicenter series (1,404 patients) found hypertrichosis in about 15% and low rates of systemic adverse effects (for example, lightheadedness, fluid retention, tachycardia), with discontinuation for adverse effects relatively uncommon; this supports tolerability at typical low doses, while still requiring individualized cardiovascular risk assessment.

Contraindications commonly include pregnancy (avoid), careful use in people with cardiovascular disease, and monitoring for edema, tachycardia, or symptomatic hypotension.

Finasteride and Dutasteride

A recent review notes oral finasteride reduces serum/scalp DHT substantially (commonly cited ~60–70%), with visible effects typically within about six months and sustained benefit with continued use in longer follow-up studies.

Sexual adverse effects are a key counseling point; meta-analytic signals for increased sexual adverse events are reported in some analyses, and reversibility is commonly described but remains a point of patient concern and ongoing debate. Testosterone-related teratogenic risk is why exposure in pregnancy is contraindicated, and use in women of childbearing potential requires robust contraception planning when off-label use is considered.

Dutasteride is a more potent 5α-reductase inhibitor (type 1 and 2) with longer half-life and is approved for AGA in some countries but remains off-label in others.

Topical Finasteride

A phase III randomized, controlled trial of topical finasteride spray in men showed significantly greater improvement in target-area hair count at 24 weeks versus placebo (about 20 hairs vs about 7 hairs), with efficacy numerically similar to oral finasteride but markedly lower systemic exposure and a smaller reduction in serum DHT. This supports topical finasteride as an option for men concerned about systemic effects, while acknowledging that long-term comparative outcomes remain less robust than for oral finasteride.

Antiandrogens for Women with AGA

Antiandrogen therapy is often considered for women with female-pattern hair loss, especially when hyperandrogenism is present. A therapeutic update notes commonly used options (spironolactone, cyproterone acetate, and in selected cases bicalutamide), but also emphasizes that high-quality evidence is limited for many antiandrogens and that combination strategies are common despite incomplete comparative trial data.

Spironolactone adverse effects include fatigue, breast tenderness, menstrual irregularity, and hypotension; hyperkalemia risk appears low in healthy young women in some retrospective data, but potassium monitoring decisions should be individualized. Pregnancy is a contraindication for antiandrogens, so contraception planning is essential.

Procedural and Device-Based Options

Procedures and devices are best viewed as adjuncts rather than replacements for core pharmacologic therapy, especially in AGA where maintenance is central.

• Platelet-rich plasma (PRP): Multiple systematic reviews and meta-analyses report improvements in hair density and/or thickness compared with baseline or controls, but heterogeneity is substantial (protocol differences, outcome measures, blinding) and publication bias is a concern.
• Microneedling: Meta-analytic evidence suggests microneedling can improve outcomes, often studied as an adjunct to topical therapy, but study quality and protocol diversity limit certainty about optimal needle depth, frequency, and long-term durability.
• Low-level light/laser therapy (LLLT): Reviews and consensus statements describe modest benefits in some patients and consider it an option for those who prefer to avoid systemic therapy or as an adjunct, with the caveat that study designs and devices vary and comparative effectiveness is uncertain.
• Hair transplantation: Most guidance positions transplantation after medical therapy has stabilized hair loss and after an adequate trial period, because ongoing miniaturization can compromise long-term aesthetics if the disease is untreated.

Practical Treatment Comparison: AGA vs TE

Prognosis, Counseling, Prevention, and Uncertainty

Prognosis and Natural History

TE is often reversible, especially when acute and trigger-linked. Post-infectious TE commonly improves over months with spontaneous regrowth, although relapse can occur, triggers can persist, and chronic-shedding labels can conceal early AGA.

AGA is chronic and tends to progress without treatment. Most therapies are better at slowing progression and improving density than at restoring a juvenile baseline, and benefits usually depend on continued use. Finding a hair loss specialist early improves the odds of preserving follicle density before miniaturization advances.

Overlap and Coexistence Scenarios

Three common overlap patterns matter clinically:

• TE unmasking early AGA: sudden shedding reveals underlying miniaturization and part widening that was subtle before.
• AGA with superimposed TE: patterned miniaturization plus a triggered shedding event. Wash testing frameworks explicitly describe criteria for "AGA + TE" based on both shedding counts and vellus-hair proportion.
• Chronic TE vs early diffuse AGA diagnostic confusion: systematic review evidence suggests diagnostic inconsistency and incomplete exclusion of alternative causes in the chronic TE literature, reinforcing the role of careful trichoscopy and, when needed, biopsy.

Patient Counseling

A few counseling points repeatedly reduce distress and improve outcomes:

• Expect the delay: TE shedding often begins months after the trigger because follicle cycling changes precede the visible shed.
• Regrowth is slow but real: even when the insult is over, follicles need time to cycle back into sustained anagen growth. A common clinical pattern is that regrowth becomes noticeable over months rather than weeks.
• Treat the right problem: TE is primarily about shedding and time; AGA is about progressive miniaturization and maintenance therapy. Confusing the two leads to disappointment: TE patients may expect instant regrowth, and AGA patients may expect TE-like "full recovery" without maintenance.
• Anticipate early minoxidil shedding: both consensus and therapeutic updates emphasize that early increased shedding can occur after starting minoxidil and should not automatically trigger discontinuation.

Lifestyle and Nutritional Advice

Lifestyle guidance should be framed as "supporting healthy cycling" rather than promising cures:

• Avoid crash dieting and severe protein restriction: dietary restriction is repeatedly cited as a TE trigger, and stable nutrition is a pragmatic preventive measure.
• Correct proven deficiencies rather than chasing marginal lab values: TE lab-testing reviews emphasize limited evidence for supplementation-driven regrowth without true deficiency and highlight the costs and harms of unnecessary testing and supplementation.
• Be cautious with "hair supplement stacks": evidence for many nutraceuticals is inconsistent, though at least one recent RCT in TE demonstrated density benefit for a specific drinkable nutraceutical in a specific population. The existence of one positive RCT does not generalize to all supplements, and long-term durability beyond the study window is often unspecified.
• Scalp health matters: treat seborrheic dermatitis or inflammatory scalp conditions when present because inflammation can contribute to shedding and symptoms, even if it is not the primary cause.

Prevention Strategies

Prevention is more feasible for TE than for AGA:

• TE prevention: reduce modifiable triggers (avoid extreme caloric restriction, support recovery after major illness, review medication changes with a clinician, and address treatable deficiencies or endocrine disorders when present). Some TE triggers (for example, postpartum hormonal shifts) are not preventable, so prevention strategies are partly situational.
• AGA prevention: true prevention is limited because genetics and androgen sensitivity are central; the more practical goal is early detection and early treatment to slow progression while follicles remain responsive.

Areas of Uncertainty or Limited Evidence

Several high-interest questions remain incompletely answered:

• Chronic TE as a distinct disease: current literature contains definitional inconsistency and limited prospective follow-up, and many cases may reflect early AGA or unidentified ongoing triggers.
• Routine TE lab panels: evidence that broad laboratory testing changes outcomes is limited; targeted testing based on history may be more defensible, but an optimal standardized algorithm remains uncertain.
• Comparative effectiveness among procedural AGA therapies (PRP, microneedling, LLLT): meta-analyses show signal of benefit for some outcomes, but heterogeneity and protocol variability limit precision about best candidates and effect size.

Conclusion